LIQUID10
Liquid biopsy NGS panel targeting 10 actionable genes for mutations & fusions commonly mutated in cancer especially lung & colon cancer to provide treatment options & prognostic indications.
LIQUID100
Liquid biopsy NGS panel targeting >100 actionable genes in cancers for mutation, fusion and SNP to provide treatment options & prognostic indications.
HOMOLOGOUS
RECOMBINATION
DEFICIENCY
(HRD)
NGS panel to assess the status
of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability.
TISSUE
PREMIUM
NGS panel targeting mutation and fusion, MSI (PCR & Fragment analysis), PD-L1 (IHC) and blood germline NGS panel targeting genes associated with hereditary cancer predisposition, enabling the identification of somatic mutations as well as inherited cancer risks in individuals.
TISSUE10
FFPE NGS panel targeting 17 actionable genes for
mutations & fusions commonly mutated in cancers to provide treatment options & prognostic indications.
CANCER
HEREDITARY
Blood germline NGS panel targeting 31 genes
associated with hereditary cancer predisposition.
ONCODEcipher Lung Premium
FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in lung cancer to provide treatment options & prognostic indications.
ONCODEcipher Breast & Ovarian Premium
FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.
ONCODEcipher Breast & Ovarian Liquid Premium
Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.
ONCODEcipher Colon & Endometrial Premium
FFPE DNA & blood panel targeting 67 relevant genetic mutations in colon and endometrial cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.
ONCODEcipher Pancreatic & Prostate Premium
FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in pancreatic and prostate cancer to provide treatment options & prognostic indications.
ONCODEcipher Tissue Premium
FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in cancerous cell tissue to provide treatment options & prognostic indications.Â
ONCODEcipher Liquid Premium
Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.
ONCODEcipher Liquid Premium Plus
Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients